Saturday, October 09, 2021 3:27:31 PM
Sigma-1 agonist shows some 9,160 results on semanticscholar.org
The latest:
CARDIAC
https://www.semanticscholar.org/paper/Yiqi-Huoxue-preserves-heart-function-by-the-Sigma-1-Lou-Li/9b09feef1cb4b1d98e46f3c34f48a62888c5b5fe
NEUROPATIC PAIN
https://www.semanticscholar.org/paper/Genomic-Action-of-Sigma-1-Receptor-Chaperone-to-Wang-Goguadze/f5ccaff7205e2a007181745518c2f2fccf62e931
EYES
https://www.semanticscholar.org/paper/Sigma-1-Receptor-Modulates-Optic-Nerve-Head-Zhao-Gonsalvez/37a52ce606bfd54cdebdfc308db91a08dc739f2a
REDUCES NEUROINFLAMMATION
https://www.semanticscholar.org/paper/Sigma-1-Receptor-Activation-Suppresses-Microglia-M1-Ooi-Hu/5ee5403006b6a03e8030b2f40f3a1ddfaa197f36
ALS
https://www.semanticscholar.org/paper/The-effect-of-%CF%831R-agonist%2Fwildtype-%CF%831R%C2%A0-on-abnormal-Shinoda-Haga/d1ffd6e2db6383b8f19d2a73b27c6284cdc8ebb3
ALZHEIMER
https://www.semanticscholar.org/paper/The-emerging-role-of-the-sigma-1-receptor-in-for-of-Prasanth-Malar/e972cddfda59b519dd1362579d8d1e63bb5a9796
The latest:
CARDIAC
https://www.semanticscholar.org/paper/Yiqi-Huoxue-preserves-heart-function-by-the-Sigma-1-Lou-Li/9b09feef1cb4b1d98e46f3c34f48a62888c5b5fe
NEUROPATIC PAIN
https://www.semanticscholar.org/paper/Genomic-Action-of-Sigma-1-Receptor-Chaperone-to-Wang-Goguadze/f5ccaff7205e2a007181745518c2f2fccf62e931
EYES
https://www.semanticscholar.org/paper/Sigma-1-Receptor-Modulates-Optic-Nerve-Head-Zhao-Gonsalvez/37a52ce606bfd54cdebdfc308db91a08dc739f2a
REDUCES NEUROINFLAMMATION
https://www.semanticscholar.org/paper/Sigma-1-Receptor-Activation-Suppresses-Microglia-M1-Ooi-Hu/5ee5403006b6a03e8030b2f40f3a1ddfaa197f36
ALS
https://www.semanticscholar.org/paper/The-effect-of-%CF%831R-agonist%2Fwildtype-%CF%831R%C2%A0-on-abnormal-Shinoda-Haga/d1ffd6e2db6383b8f19d2a73b27c6284cdc8ebb3
ALZHEIMER
https://www.semanticscholar.org/paper/The-emerging-role-of-the-sigma-1-receptor-in-for-of-Prasanth-Malar/e972cddfda59b519dd1362579d8d1e63bb5a9796
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
